No Data
No Data
Jiangsu Jibeier Pharmaceutical (SHSE:688566) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) robust earnings report didn't manage to move the market for its stock. Our analysis suggests that shareholders have noticed something concerni
Gibbel (688566): Sales reforms continue to promote rapid release of core products
Event: Jebel announced on April 26, 2024: In 2023, the company achieved operating income of 861 million yuan, an increase of 31.49% over the previous year; net profit to mother was 219 million yuan, an increase of 41.65% over the previous year
Gibbel (688566.SH) released 2023 annual results, with net profit of 219 million yuan, an increase of 41.65% over the previous year
Gibbel (688566.SH) released its 2023 annual report. The company achieved operating income of 8.6 during the reporting period...
Jiangsu Jibeier Pharmaceutical Co., Ltd.'s (SHSE:688566) 11% Gain Last Week Benefited Both Private Companies Who Own 37% as Well as Insiders
Key Insights Jiangsu Jibeier Pharmaceutical's significant private companies ownership suggests that the key decisions are influenced by shareholders from the larger public A total of 2 investors hav
Could The Market Be Wrong About Jiangsu Jibeier Pharmaceutical Co., Ltd. (SHSE:688566) Given Its Attractive Financial Prospects?
It is hard to get excited after looking at Jiangsu Jibeier Pharmaceutical's (SHSE:688566) recent performance, when its stock has declined 11% over the past three months. However, stock prices are us
Gibbel (688566): Core products help high performance growth, and the innovation pipeline is expected to continue to catalyze
Liquorjun tablets: Exclusive whitening drug with obvious advantages in curative efficacy and safety, and the expansion of multi-departmental applications has brought new volume. Liquorjun tablets are drugs used to prevent and treat leukocytopenia. They are stable, highly safe, and suitable for long-term use
No Data